ASCO 2026 wasn’t just about new data—it highlighted where oncology is headed next. From breakthrough in vivo CAR-T results and RAS-targeted therapies to the growing influence of Chinese biotech on the global stage, this year’s meeting showcased the evolving future of cancer care. Listen to the recap: https://www.fiercepharma.com/pharma/behind-headlines-asco-2026
More Tips From The Bandish Group
A Potential Milestone in HIV Treatment
◆
New Phase 3 data from Gilead Sciences and Merck support what could become the first complete once-weekly oral treatment for…
How Small Businesses Can Master Team Communication to Cut Conflicts and Check-Ins
◆
By Marjorie McMillian For small business owners managing lean teams, workplace communication challenges rarely look serious at first. A quick…